Bcr-Abl
Gli inibitori di Bcr-Abl sono terapie mirate che inibiscono la proteina di fusione Bcr-Abl, formata a seguito della traslocazione del cromosoma Philadelphia e responsabile della leucemia mieloide cronica (CML). Questa proteina influenza anche l'angiogenesi, contribuendo alla progressione tumorale. Gli inibitori di Bcr-Abl sono cruciali nel trattamento della CML e sono oggetto di ricerca per il loro potenziale nell'inibire l'angiogenesi in vari tipi di cancro. Presso CymitQuimica, offriamo inibitori di Bcr-Abl di alta qualità per supportare la tua ricerca in biologia del cancro, angiogenesi e terapie mirate.
Trovati 116 prodotti di "Bcr-Abl"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Dasatinib
CAS:<p>Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.</p>Formula:C22H26ClN7O2SPurezza:99.59% - 99.86%Colore e forma:Pale-Yellow SolidPeso molecolare:488.01Imatinib Mesylate
CAS:<p>Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,</p>Formula:C29H31N7O·CH4SO3Purezza:98% - >99.99%Colore e forma:White Crystalline PowderPeso molecolare:589.71Bosutinib
CAS:Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formula:C26H29Cl2N5O3Purezza:98.98% - 99.9%Colore e forma:Yellowish-Orange Or Pink To Brownish Solid Solid PowderPeso molecolare:530.45Nilotinib
CAS:<p>Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.</p>Formula:C28H22F3N7OPurezza:99.89% - >99.99%Colore e forma:Off-White SolidPeso molecolare:529.52N-Desmethyl imatinib
CAS:N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Formula:C28H29N7OPurezza:98.60%Colore e forma:Off-White To Pale-Yellow SolidPeso molecolare:479.58Lyn-IN-1
CAS:Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and LynFormula:C30H31F3N8OPurezza:97% - 98.02%Colore e forma:SolidPeso molecolare:576.62AKE-72
CAS:<p>AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.</p>Formula:C30H29F3N6OPurezza:98.3%Colore e forma:SoildPeso molecolare:546.59Dasatinib monohydrate
CAS:Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.Formula:C22H28ClN7O3SPurezza:99.68% - >99.99%Colore e forma:SolidPeso molecolare:506.03LXH254
CAS:LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Formula:C25H25F3N4O4Purezza:98.3% - 99.92%Colore e forma:SolidPeso molecolare:502.49ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Formula:C47H53BrCl2N10O7SPurezza:98%Colore e forma:SolidPeso molecolare:1052.86SIAIS178
CAS:SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formula:C50H62ClN11O6S2Purezza:98.07%Colore e forma:SolidPeso molecolare:1012.68c-ABL-IN-5
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability,Formula:C19H17F2N3OPurezza:98%Colore e forma:SolidPeso molecolare:341.35FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Colore e forma:LiquidPROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formula:C17H12F3N3O2Colore e forma:SoildPeso molecolare:347.29SNIPER(ABL)-047
SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,Formula:C67H82F3N11O9SPurezza:98%Colore e forma:SolidPeso molecolare:1274.5BCR-ABL-IN-3
CAS:BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.Formula:C20H17ClF2N4O3SColore e forma:SolidPeso molecolare:466.89SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Formula:C44H59ClN10O8SPurezza:98%Colore e forma:SolidPeso molecolare:923.52SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormula:C60H77ClN12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1177.85Imatinib impurities3
CAS:<p>Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.</p>Formula:C24H20ClN5OPurezza:98.63%Colore e forma:SolidPeso molecolare:429.9FGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Formula:C28H26Cl2N4O3Colore e forma:SolidPeso molecolare:537.44SNIPER(ABL)-013
SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 ofFormula:C42H52F3N7O8Purezza:98%Colore e forma:SolidPeso molecolare:839.9SNIPER(ABL)-015
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5Formula:C58H70F3N9O9Purezza:98%Colore e forma:SolidPeso molecolare:1094.23SNIPER(ABL)-050
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.Formula:C68H84N12O9Purezza:98%Colore e forma:SolidPeso molecolare:1213.47SNIPER(ABL)-039
CAS:SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 ofFormula:C54H68ClN11O9S2Purezza:98%Colore e forma:SolidPeso molecolare:1114.77SNIPER(ABL)-033
CAS:SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL proteinFormula:C61H73F3N10O9S2Purezza:98%Colore e forma:SolidPeso molecolare:1211.42DPH
CAS:DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Formula:C18H13FN4O2Purezza:99.65%Colore e forma:SolidPeso molecolare:336.32AD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurezza:99.05%Colore e forma:SoildPeso molecolare:455.44MRT-7612
MRT-7612 (Compound 4) is a cereblon-based molecular glue degrader targeting tyrosine kinases. It significantly induces the degradation of HCK and LYN, with a comparatively weaker effect on LCK. MRT-7612 is applicable in research related to cancers such as chronic myeloid leukemia, autoimmune disorders, and chronic inflammatory diseases.Colore e forma:Odour SolidcSRC/BCR-ABL-IN-1
cSRC/BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.Formula:C29H31Cl2N5O4Colore e forma:SolidPeso molecolare:584.494Tyrosine kinase-IN-8
Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI) exhibiting antiproliferative activity against the chronic myeloid leukemia (CML) cell line K562, with a CC50 of 0.8 µM. Tyrosine kinase-IN-8 is applicable for research in chronic leukemia.Formula:C31H21F2N7O2Peso molecolare:561.17248Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Colore e forma:Odour SolidTyrosine Kinase Inhibitor Library
A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase relatedColore e forma:Odour SolidAbl Cytosolic Substrate
CAS:Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Formula:C64H101N15O16Purezza:98%Colore e forma:SolidPeso molecolare:1336.58SNIPER(ABL)-058
CAS:SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL proteinFormula:C62H75N11O9SPurezza:98%Colore e forma:SolidPeso molecolare:1150.39PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormula:C43H40N10O6Purezza:98%Colore e forma:SolidPeso molecolare:792.84SNIPER(ABL)-044
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving aFormula:C51H64F3N9O8SPurezza:98%Colore e forma:SolidPeso molecolare:1020.17SNIPER(ABL)-049
SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,Formula:C52H66N10O8Purezza:98%Colore e forma:SolidPeso molecolare:959.14BCR-ABL-IN-10
<p>BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).</p>Formula:C24H22N4O5SColore e forma:SolidPeso molecolare:478.52SNIPER(ABL)-024
CAS:SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formula:C52H61F3N8O9SPurezza:98%Colore e forma:SolidPeso molecolare:1031.15SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColore e forma:SolidPeso molecolare:890.44cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Formula:C24H27ClN6O4Colore e forma:SolidPeso molecolare:498.96BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formula:C22H20N4O3Colore e forma:SolidPeso molecolare:388.42TG-100435
CAS:TG-100435 is a novel multi-target oral protein tyrosine kinase inhibitor. The metabolic flux of TG100435 is entirely inhibited by methimazole and ketoconazole. In human liver microsomes or recombinant P450, the formation of TG100435 increases with the activity of cytochrome P450 reductase, suggesting that cytochrome P450 reductase may be involved.Formula:C26H25Cl2N5OPeso molecolare:494.42HG-7-85-01-NH2
CAS:HG-7-85-01-NH2, as the ligand for SNIPER(ABL)-033, effectively induces the reduction of BCR-ABL protein. This is achieved through SNIPER(ABL)-033, which connects HG-7-85-01 (an ABL inhibitor) to an LCL161 derivative (an IAP ligand) using a linker, demonstrating a DC50 value of 0.3 μM [1].Formula:C27H27F3N6OSColore e forma:SolidPeso molecolare:540.6c-ABL-IN-1
CAS:C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's diseaseFormula:C17H16Cl2FN3OSColore e forma:SolidPeso molecolare:400.29Asciminib hydrochloride
CAS:Asciminib hydrochloride is a STAMP inhibitor targeting the ABL myristoyl pocket, applied in Ph+ CML research for selective oncogenic signaling modulation.Formula:C20H19Cl2F2N5O3Purezza:99.91%Colore e forma:SolidPeso molecolare:486.3BGG463
CAS:BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Formula:C30H29F3N6O3Purezza:98.21% - >99.99%Colore e forma:SolidPeso molecolare:578.58GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formula:C28H24F3N7O2Purezza:97.05% - 99.7%Colore e forma:SolidPeso molecolare:547.53Degrasyn
CAS:Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.Formula:C19H18BrN3OPurezza:98.32% - 99.98%Colore e forma:SolidPeso molecolare:384.27Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formula:C14H11N3O3SPurezza:98% - 99.91%Colore e forma:Physical Description White Powder (Ntp 1992)Peso molecolare:301.32Rebastinib
CAS:<p>DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,</p>Formula:C30H28FN7O3Purezza:99.53% - 99.79%Colore e forma:SolidPeso molecolare:553.59Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormula:C29H27F3N6OPurezza:98% - 99.60%Colore e forma:SolidPeso molecolare:532.56NVP-BAW2881
CAS:NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor with activity to inhibit chronic and acute skin inflammation.Formula:C22H15F3N4O2Purezza:98.19% - 99.97%Colore e forma:SolidPeso molecolare:424.38AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formula:C19H23N7O2Purezza:99.83% - 99.98%Colore e forma:SolidPeso molecolare:381.43Multi-kinase inhibitor 1
CAS:Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.Formula:C20H17F3N4O3Purezza:99.34%Colore e forma:SolidPeso molecolare:418.37Flumatinib
CAS:Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.Formula:C29H29F3N8OPurezza:99.39% - 99.95%Colore e forma:SolidPeso molecolare:562.59AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formula:C14H13BrN2OPurezza:98% - 99.37%Colore e forma:SolidPeso molecolare:305.17Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formula:C29H27F3N6O·2CH4O3SPurezza:97.66% - >99.99%Colore e forma:SolidPeso molecolare:724.77Dasatinib N-oxide
CAS:<p>Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.</p>Formula:C22H26ClN7O3SPurezza:98.54% - 99.94%Colore e forma:SolidPeso molecolare:504Olverembatinib
CAS:Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Formula:C29H27F3N6OPurezza:98.53% - >99.99%Colore e forma:SolidPeso molecolare:532.56NVP-BHG712
CAS:NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src andFormula:C26H20F3N7OPurezza:97.32% - 98.63%Colore e forma:SolidPeso molecolare:503.48Agerafenib
CAS:Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.Formula:C24H22F3N5O5Purezza:95.78% - 99.23%Colore e forma:SolidPeso molecolare:517.46GNF-2
CAS:GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.Formula:C18H13F3N4O2Purezza:98.17% - ≥95%Colore e forma:SolidPeso molecolare:374.32GMB-475
CAS:GMB-475, a PROTAC-based BCR-ABL1 inhibitor, tackles drug resistance by promoting VHL-mediated degradation.Formula:C43H46F3N7O7SPurezza:98.78% - >99.99%Colore e forma:SolidPeso molecolare:861.93KW-2449
CAS:KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Formula:C20H20N4OPurezza:98.43% - 99.69%Colore e forma:SolidPeso molecolare:332.4Asciminib
CAS:<p>Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).</p>Formula:C20H18ClF2N5O3Purezza:98.82% - 99.70%Colore e forma:SolidPeso molecolare:449.84Imatinib
CAS:Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kitFormula:C29H31N7OPurezza:99.42% - 99.94%Colore e forma:Off White PowderPeso molecolare:493.6Vodobatinib
CAS:Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.Formula:C27H20ClN3O2Purezza:99.06% - 99.55%Colore e forma:SolidPeso molecolare:453.92XL228
CAS:XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).Formula:C22H31N9OPurezza:99.07%Colore e forma:SolidPeso molecolare:437.54Bafetinib
CAS:<p>Bafetinib (INNO-406): Dual Bcr-Abl/Lyn inhibitor; IC50: 5.8/19 nM; ineffective against T315I mutant, less on c-Kit/PDGFR.</p>Formula:C30H31F3N8OPurezza:94.16% - 99.68%Colore e forma:SolidPeso molecolare:576.62GNF-5
CAS:GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.Formula:C20H17F3N4O3Purezza:98% - 99.94%Colore e forma:SolidPeso molecolare:418.37Flumatinib mesylate
CAS:<p>Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.</p>Formula:C30H33F3N8O4SPurezza:99.82%Colore e forma:SolidPeso molecolare:658.69CZC-8004
CAS:<p>CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.</p>Formula:C17H16FN5Purezza:99.29%Colore e forma:SolidPeso molecolare:309.34Adaphostin
CAS:Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.Formula:C24H27NO4Purezza:98.29%Colore e forma:SolidPeso molecolare:393.48Nilotinib monohydrochloride monohydrate
CAS:<p>Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosine</p>Formula:C28H22F3N7O·HCl·H2OPurezza:99.93%Colore e forma:SolidPeso molecolare:583.99AST 487
CAS:AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.Formula:C26H30F3N7O2Purezza:98.17% - 99.56%Colore e forma:SolidPeso molecolare:529.56PD173955
CAS:<p>PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and</p>Formula:C21H16Cl2N4OSPurezza:98.52% - 98.99%Colore e forma:SolidPeso molecolare:443.35Bosutinib hydrate
CAS:Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.Formula:C26H31Cl2N5O4Purezza:99.87%Colore e forma:SolidPeso molecolare:548.46c-ABL-IN-4
CAS:c-ABL-IN-4 is a potent inhibitor of c-Abl.Formula:C18H11ClF3N3O3Colore e forma:SolidPeso molecolare:409.75c-ABL-IN-3
CAS:c-ABL-IN-3, from patent WO2021048567A1, is a potent c-Abl inhibitor for researching ALS, PD, and cancer.Formula:C17H11F3N4O3Colore e forma:SolidPeso molecolare:376.29BCR-ABL-IN-5
CAS:BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.Formula:C25H21Cl2N5O2Colore e forma:SolidPeso molecolare:494.37CHMFL-ABL-053
CAS:CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.Formula:C28H26F3N7O2Colore e forma:SolidPeso molecolare:549.55AFG210
CAS:AFG210 is a novel first-generation “type II” FLT3 inhibitor.Formula:C19H14F3N3O2Colore e forma:SolidPeso molecolare:373.33BCR-ABL1-IN-1
CAS:BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.Formula:C18H12F3N3O2Colore e forma:SolidPeso molecolare:359.3AP 24149
CAS:AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.Formula:C23H24N5OPColore e forma:SolidPeso molecolare:417.44BCR-ABL-IN-2
CAS:BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).Formula:C24H25Cl2N5O3Purezza:98%Colore e forma:SolidPeso molecolare:502.39BCR-ABL-IN-7
CAS:BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.Formula:C19H16FN3O3SPurezza:98.28%Colore e forma:SolidPeso molecolare:385.41CpCDPK1/TgCDPK1-IN-1
CAS:CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.Formula:C18H17N5Purezza:99.61%Colore e forma:SolidPeso molecolare:303.36PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Formula:C26H29Cl2N5O3Purezza:97.01%Colore e forma:SolidPeso molecolare:530.45BCR-ABL-IN-1
CAS:BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.Formula:C23H21F4N5OPurezza:98%Colore e forma:SolidPeso molecolare:459.44Antiproliferative agent-30
CAS:Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM againstFormula:C24H26N4O4Colore e forma:SolidPeso molecolare:434.49c-ABL-IN-2
CAS:C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.Formula:C21H20N4OColore e forma:SolidPeso molecolare:344.41Debio 0617B
CAS:Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.Formula:C28H23ClF3N7O2Colore e forma:SolidPeso molecolare:581.98BGB659
CAS:BGB659 is effective inhibitor of RAF.Formula:C29H29F3N4O3Purezza:98%Colore e forma:SolidPeso molecolare:538.56Tyrphostin AG 568
CAS:Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.Formula:C13H9N5O2Purezza:98%Colore e forma:SolidPeso molecolare:267.24ON 146040
CAS:ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.Formula:C24H23N7O3SPurezza:97.39%Colore e forma:SolidPeso molecolare:489.55PD-173956
CAS:PD-173956 is an inhibitor of the Src family tyrosine kinases.Formula:C20H13Cl2FN4OColore e forma:SolidPeso molecolare:415.25AN-019
CAS:AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.Formula:C25H17F6N5OPurezza:98.99%Colore e forma:SolidPeso molecolare:517.43BCR-ABL-IN-6
CAS:BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.Formula:C27H22F3N5O2Colore e forma:SolidPeso molecolare:505.49PPY A
CAS:PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase and inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl gene-transformed cellsFormula:C22H20N4O2Purezza:98.77%Colore e forma:SolidPeso molecolare:372.42
